Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
973.9
¥ millionWording
Conditional
How definitive the wording is.Details of issuance or disposal
Issuance through a third-party allotment of new shares and the 19th and 20th Series Stock Acquisition Rights (with Provisions for Adjustment of the Exercise Price)
Amount of funds to be raised
Estimated net proceeds: ¥3,721.9 million
Specific use of funds
Costs of the CBP501 Phase 3 clinical trialAmount ¥3,271.9 million / Scheduled timing of expenditures May 2023 to August 2028
Operating funds (basic research expenses, selling, general and administrative expenses)Amount ¥1,560 million / Scheduled timing of expenditures July 2023 to August 2026
Terms of the stock acquisition rights
Exercise price
The 20th Series Stock Acquisition Rights are described as having provisions for adjustment of the exercise price, but the initial exercise price and adjustment floor are Not disclosed.
Most recent equity financing
Timing 2 June 2023 / Type Issuance of new shares and the 19th and 20th Series Stock Acquisition Rights / Amount Estimated net proceeds: ¥3,721.9 million, Timing Not disclosed / Type 17th Stock Acquisition Rights / Amount Approximately ¥1,110 million
Impact on Business Performance
This change will have no impact on the company's results for the current fiscal year.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance through a third-party allotment of new shares and the 19th and 20th Series Stock Acquisition Rights (with Provisions for Adjustment of the Exercise Price) |
| Amount of funds to be raised | Estimated net proceeds: ¥3,721.9 million |
| Specific use of funds | Details Costs of the CBP501 Phase 3 clinical trial / Amount ¥3,271.9 million / Scheduled timing of expenditures May 2023 to August 2028, Details Operating funds (basic research expenses, selling, general and administrative expenses) / Amount ¥1,560 million / Scheduled timing of expenditures July 2023 to August 2026 |
| Exercise price | The 20th Series Stock Acquisition Rights are described as having provisions for adjustment of the exercise price, but the initial exercise price and adjustment floor are Not disclosed. |
| Most recent equity financing | Timing 2 June 2023 / Type Issuance of new shares and the 19th and 20th Series Stock Acquisition Rights / Amount Estimated net proceeds: ¥3,721.9 million, Timing Not disclosed / Type 17th Stock Acquisition Rights / Amount Approximately ¥1,110 million |
| Impact on Business Performance | This change will have no impact on the company's results for the current fiscal year. |
Items this document does not state (22)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Approval to commence the CBP501 Phase 3 clinical trial in the United States was not obtained, eliminating the need to allocate funds to the expenses planned for the United States, while preparations and procedures for an application to the European Medicines Agency (EMA) are under way. Operating funds were also spent in excess of the originally planned amount because of funding needs.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.